期刊文献+

宁波地区耐多药结核分枝杆菌链霉素耐药相关基因rpsL和rrs突变研究 被引量:4

Mutation of streptomycin-resistant genes rpsL and rrsin multidrug-resistant Mycobacterium tuberculosis isolates in Ningbo
原文传递
导出
摘要 目的阐明宁波地区耐多药结核分枝杆菌链霉素耐药相关基因rpsL和rrs的分子突变特征,为宁波地区耐多药结核病的有效防控提供科学依据。方法从宁波市疾病预防控制中心收集67例耐多药结核分枝杆菌临床分离株,包括耐链霉素菌株40株和链霉素敏感菌株27株。采用PCR直接测序法分析rpsL和rrs基因的分子突变特征。对链霉素耐药与基因突变率关系之间的差异采用χ2检验,P<0.05为差异有统计学意义。结果 40株耐链霉素菌株中,31株(77.50%)检测到rpsL发生突变。突变位点集中在第43位和第88位密码子;6株耐链霉素菌株(15.00%)检测到2种不同类型的rrs基因突变,分别为A1401G(7.50%,3/40);A514C(7.50%,3/40)。27株链霉素敏感菌株中有4株(14.81%)发生rpsL突变,突变位点集中在第104位和第119位密码子,1株链霉素敏感菌株的rrs基因检测到A1401G突变。耐多药结核分枝杆菌中链霉素耐药株rpsL基因突变率高于链霉素敏感株,两者之间差异有统计学意义(χ2=25.387,P<0.05)。结论宁波地区耐多药结核分枝杆菌对链霉素的耐药与rpsL突变高度相关,耐药基因突变类型存在地域差异。 Objective To discuss the mutation of streptomycin-resistant genes rpsLand rrsin multidrug-resistant Mycobacterium tuberculosis isolates in Ningbo. Methods 67multidrug-resistant Mycobacterium tuberculosis isolates were collected from Ningbo Municipal Center for Disease Control and Prevention,including 40streptomycin(SM)-resistant isolates and 27 non streptomycin-resistant isolates.The mutation of rpsLand rrs genes were analyzed by PCR and sequencing. Results rpsL mutations were found in 31SM-resistant clinical isolates(77.50%),and rpsL Lys43 Arg and Lys88 Arg were the most common mutation sites.Two types of mutations of rrs gene including A1401G(7.50%,3/40),A514C(7.50%,3/40)were identified in 6SM-resistant isolates(15.00%).rpsL mutations were found in 4SM-susceptible clinical isolates(14.81%),and rpsL Ala119 Gly was the most common mutation site.Only one type of rrs mutation A1401 G was identified in one SM-susceptible isolate.The rpsLgene mutation rate in SM resistant strains was significantly higher than that in SM-susceptible strains(χ^2=25.387,P〈0.05). Conclusions The rpsLgene mutation in multidrug-resistant Mycobacterium tuberculosis isolates is highly associated with streptomycin resistance,and the mutation type varies due to geographical difference.
作者 车洋 杨天池 平国华 林律 CHE Yang YANG Tian-chi PING Guo-hua LIN Lu(Ningbo Municipal Center for Disease Control and Prevention, Ningbo, Zhejiang 315010, China)
出处 《中国预防医学杂志》 CAS 2016年第10期744-749,共6页 Chinese Preventive Medicine
基金 宁波市2015年第二批科技项目(2015A610195)
关键词 耐多药结核 链霉素 RPSL基因 rrs基因 Multi-drug resistance Streptomycin rpsLgene rrs gene
  • 相关文献

参考文献19

  • 1He GX, Zhao YL, jiang GL, et al. Prevalence of tuberculo- sis drug resistance in 10 provinces of China [J]. BMC Infect Dis, 2008, 8 (1): 166-168.
  • 2魏淑贞,林淑芳,陈求扬,梁庆福,赵永,林建,林勇明,万康林,郑金凤.福建省耐多药结核分枝杆菌相关耐药基因突变特征分析[J].中国预防医学杂志,2013,14(5):353-356. 被引量:2
  • 3Jana S, Deb JK. Molecular understanding of aminoglycoside action and resistance [J]. Appl Microbiol Biotechnol, 2006, 70 (2): 140-150.
  • 4Morris RP, Nguyen L, Garfield J, et al. Ancestral antibiotic resistance in Mycohacterium tuberculosis [J]. Proc Natl AcadSciUSA, 2005, 102 (34): 12200-12205.
  • 5Jnawali HN, Yoo H, Ryoo S, et al. Molecular genetics of Mycobacterium tuberculosis resistant to aminoglycosides and cyclic peptide capreomycin antibiotics in Korea[J]. World J Mierobiol Biotechnol, 2013, 29 (6): 975-982.
  • 6Cuevas Cerdoba B, Cuellar Sdnchez A, Pasissi Crivelli A, et al. rrs and rpsL mutations in streptomycin-resistant iso- lates of Mycobacterium tuberculosis from Mexico [J]. J Mi crobiolImmunolInfect, 2013, 46 (1): 30-34.
  • 7Tude G, Rey E, Borrell S, et al. Characterization of muta tions in streptomycin-resistant Mycobacterium tuberculosis clinical isolates in the area of Barelona [J]. J Antimicrob Chemother, 2010, 65 (11): 2341-2346.
  • 8Shi R, Zhang J, Li C, et al. Detecion of streptomycin re- sistance in Mycobacterium tuberculosis clinical isolates from China as determined by denaturing HPLC analysis and DNA sequencing[J]. Microbes Infect, 2007, 9 (14-15): 1538-1544.
  • 9Githui WA, Jordaan AM, Juma ES, et al. Identification of MDR TB Beijing/W and other Mycobacterium tuberculosis genotypes in Nairobi, Kenya[J].Int J Tuberc Lung Dis,2004, 8 (3): 352 -360.
  • 10Chen L, Li N, Liu Z, etal. Genetic diversity and drug sus- ceptibility of Mycobaeterium tuberculosis isolates from Zu- nyi, one of the highest incidence-rate areas in China [J]. J Clin Microbiol, 2012, 50 (3):1043-1047.

二级参考文献16

  • 1公众抗生素使用行为调查分析报告[J].当代医学,2005,11(7):78-80. 被引量:2
  • 2张国龙,杜长梅,苍泽卓也,池田雄史,王伟,石瑞如.中日合作对河南省结核菌二线药物耐药监测研究[J].医药论坛杂志,2005,26(19):14-16. 被引量:15
  • 3Raviglione MC. Uplekar MW. WHO' s new Stop TB Strategy [J].Lancet, 2006, 367 (9514):952 -955.
  • 4Communicable Diseases WHO. Guidelines for drug susceptibiti- ty testing for second-line antituberculosis drugs for DOTS-plus [M] .Geneva: WHO, 2001: 7.
  • 5WHO/IUATLD. Anti tuberculosis drug resistance in the world. Geneva: The WHO/IUATLD global project on anti tubercu- losis drug resistance surveillance. Report No. 2: Prevalence and Trends, 2000.
  • 6Kam KM, Yip CW. Surveillance of Mycobacterium tuberculo- sis susceptibility to second line drugs in HongKong, 1995- 2002, after the implementation of DOTS-Plus [J]. Int J Tu bercLung Dis, 2004, 8 (6): 760-766.
  • 7WMwaikar PP, Morge VK, Gawde AS. Ofloxacin in multidrug resistant tuberculosis [J].Indian Med Assoc, 2003, 101 (3): 210- 212.
  • 8WHO. Guidelines for the programmatic management of drug- re- sistant tuberculosis [M].Geneva: WHO, 2006: 361.
  • 9中华人民共和国卫生部.全国结核病耐药性基线调查报告(2007-2008年)[M].北京:人民卫生出版社,2010:51.
  • 10A Wright, G Bai, L Barrera, et al. Emergence of Mycobacte- rium tuberculosis with extensive resistance to second-linc drugs worldwide, 2000-2004 [J]. MMWR Morb Mortal Wkly Rep, 2006, 55: 301-305.

共引文献16

同被引文献42

引证文献4

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部